Addex Therapeutics Files 6-K with Press Release
Ticker: ADXN · Form: 6-K · Filed: Jun 6, 2025 · CIK: 1574232
Sentiment: neutral
Topics: filing, press-release, registration-statement
TL;DR
Addex Therapeutics dropped a press release on 6/6/25, filed it with the SEC, and it's now part of their F-3 and S-8 filings.
AI Summary
On June 6, 2025, Addex Therapeutics Ltd. issued a press release, incorporated as Exhibit 99.1 to this Form 6-K filing. This press release is being incorporated by reference into existing registration statements on Form F-3 (Registration No. 333-255089) and Form S-8 (Registration Nos. 333-255124 and 333-).
Why It Matters
This filing indicates that Addex Therapeutics has issued a press release, which may contain important updates for investors regarding the company's operations or strategic direction.
Risk Assessment
Risk Level: low — This filing is a routine submission of a press release and does not contain new financial information or significant operational changes.
Key Players & Entities
- Addex Therapeutics Ltd. (company) — Registrant
- June 6, 2025 (date) — Date of press release and filing
- Exhibit 99.1 (document) — Incorporated press release
- 333-255089 (registration_number) — Form F-3 registration statement
- 333-255124 (registration_number) — Form S-8 registration statement
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report a press release issued by Addex Therapeutics Ltd. on June 6, 2025, and incorporate it by reference into existing SEC filings.
What is the date of the press release being filed?
The press release was dated June 6, 2025.
Which registration statements are being updated by this filing?
This filing is incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) and the registration statements on Form S-8 (Registration Nos. 333-255124 and 333-).
What is the company's principal executive office address?
The company's principal executive office is located at Chemin des Mines 9, CH-1202 Geneva, Switzerland.
Does Addex Therapeutics file annual reports under Form 20-F or 40-F?
Addex Therapeutics files annual reports under Form 20-F, as indicated by the checkmark next to it.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 6, 2025 regarding Addex Therapeutics Ltd. (ADXN).